Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.

Home-grown therapies account for 80 per cent of approvals in first six months of the year.

Push to accelerate novel drug reviews promises earlier access to breakthrough therapies for patients long left waiting.